Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF) (DHELIVER)

  • End date
    Jan 23, 2023
  • participants needed
  • sponsor
    Promethera Therapeutics
Updated on 23 March 2022
dose regimen


This is an interventional, double blind, randomized (2:1), and placebo-controlled study of 1 dose regimen of HepaStem in patients recently diagnosed (≤1 week) with ACLF grade 1 or 2 on top of Standard of Care (SoC), and for whom the diagnosis is not resolved on the day of infusion.

Condition Acute on Chronic Liver Failure
Treatment Placebo, HepaStem
Clinical Study IdentifierNCT04229901
SponsorPromethera Therapeutics
Last Modified on23 March 2022


Yes No Not Sure

Inclusion Criteria

Initial diagnostic of ACLF, at the investigational site, maximum 3 days before signature of the ICF
Patient with Acute on Chronic Liver Failure Grade 1 or 2 according to the CLIF definition
Bilirubin value ≥5 mg/dL

Exclusion Criteria

ACLF grade 3
Active uncontrolled bleeding or patient with high risk of short term bleeding up to investigator's judgment
Model for End-Stage Liver Disease (MELD) score >35\
Cerebrovascular, myocardial, limb arterial thrombotic event, or history for both thrombotic and hemorrhagic cerebrovascular events within 12 months prior to the screening and not considered stabilized by the investigator
Mechanical ventilation due to respiratory failure, except for hepatic encephalopathy
Inability to maintain mean BP >60 despite use of vasopressors
Patients receiving immunosuppressive drugs, except glucocorticoids
Thrombosis of portal vein
Underlying cirrhosis due to biliary disease or auto immune hepatitis
Coagulation disturbances defined as (Drolz et al. 2016; Nadim et al. 2016)
fibrinogen <80 mg/dL
platelets <50 x 10³/mm3
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note